Welcome to EQUITY DEVELOPMENT
The UK's longest established regulated provider of sponsored equity research.
We launched EQUITY DEVELOPMENT in 1997 becoming the first ever regulated provider of Sponsored Equity Research in the UK.
Our research teams are made up of expert analysts with deep understanding & experience in their sectors. Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).
We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.
Search for Company Research
FREE REGISTRATION
Sign up today and access the very latest company research
LOG IN
For access to all company research please
Healthcare Locums
Healthcare Locums (HLO) is an established provider of specialist staff to the health and social care sectors.
Results show strategy working
Strong interim results show robust demand for healthcare professionals
Group well positioned after bold acquisition strategy
Further organic growth expected in a market favoured by demographics
2008 projections increased
8.6x PER 2008 leaves significant upside to fair value seen at 150p / share
Creating value organically
Acquisition program complete
Well placed in chosen segments
150p target value vs. current 93p
Healthcare Locums; Confident trading update
There have been mixed signals from the healthcare locum (temporaries) market recently, but still revealing the scope for nimble recruiters to prosper.
Healthcare Locums; results provide hard evidence of strategy execution
- Fair price 100p vs current 66.75p
- Acquisitions integrated
- Rating (7.5x 2007) still too low
Healthcare Locums; niche player in a growing market
- Simple model supplying specialist staff to health and social care sectors
- Growing organically and through acquisition
- 'Approved Operator' for NHS and depth of management experience
- Conservative PER still sets 100p/share target vs. current 58p
